Eye

"Anterior uveitis is often a symptom and not just a diagnosis." Dr. J Kolfenbach reminds us to remember to look deeper for underlying causes during his #ACR22 Secrets and Pearls lecture. @RheumNow

Dr. Rachel Tate @uptoTate( View Tweet )

Nov 14, 2022

Tofa 5 mg BID successful in treating refractory uveitis in reducing inflammation and reducing steroid dosage. Abs 1041 #ACR22 @RheumNow https://t.co/dtAEhW7dEG https://t.co/Xbw2iEsYHh

Links:

Tofacitinib in Refractory Uveitis – an Observational Study - ACR Meeting Abstra…

Dr. Rachel Tate @uptoTate( View Tweet )

Nov 13, 2022

Differences between #uveitis pattern in AS vs. PsA and IBD 👇 This is always asked to our rheum fellows during Kelley's hour 🤓 #ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06

sheila @RHEUMarampa( View Tweet )

Nov 13, 2022

GPA pts can have dacryoadenitis (ddx 👇) where pt's lateral eye/s can be curved due to swelling. How to examine? Use thumb to retract eyelid & reveal lacrimal gland underneath, ask pt to look medially #ACR22 @RheumNow @rheumarhyme @doktora_ging @PhRheumaJr #RheumTwitter https://t.co/pJYMffhYWx

sheila @RHEUMarampa( View Tweet )

Nov 13, 2022

👁 What causes worse outcomes in our SpA uveitis pts? 👁 🚬 smoking Hx 🦴 ax + peripheral disease ✏️ BASDAI >4 👩‍🔬 HLA B27 +ve 🙋‍♀️ females 🧪CRP ⬆️ 👁 bilat eye involvement Abst#0373 #ACR22 @RheumNow

Patricia Harkins @DrTrishHarkins( View Tweet )

Nov 12, 2022

2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis
Save

Jack Cush, MD

Oct 24, 2022

Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).

Read Article

Heavy Metal Rheumatology (9.23.2022)
Save

Jack Cush, MD

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article

Hydroxychloroquine Dosing and SLE Flares
Save

Jack Cush, MD

Sep 19, 2022

A cohort study examining hydroxychloroquine dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, in accordance with current ophthalmology and rheumatology guidelines, was associated with a higher risk of lupus flares, including moderate or severe lupus flares.

Read Article

What Worries You, Masters You (7.1.2022)
Save

Jack Cush, MD

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com. Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

FDA approved Abbvies risakizumab-rzaa

Read Article

Multinational recs. on Rx of JIA assoc. Uveitis: - Topical steroids are 1st line Rx - Systemic Rx if above fails or w/ poor prognosis or persistence - Options MTX, MMF then Humira EOW, then weekly ADA - Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd

Links:

https://bit.ly/3OpClpU

Dr. John Cush @RheumNow( View Tweet )

Jun 25, 2022

#EULAR2022 ASAS/EULAR AxSpA Recs ⭐️Last: 2016 ▶️All: education, exercise, 🚭 ▶️❌csDMARD for axial disease ▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1 ▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17 ▶️Sustained remission: tapering of bDMARD "can be considered" @RheumNow https://t.co/3yYU0Vb37r

Eric Dein @ericdeinmd( View Tweet )

Jun 02, 2022

Consequences of TNF inhibition (3.18.2022)
Save

Jack Cush, MD

Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article

2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR

Links:

https://bit.ly/3IWlWGh

Dr. John Cush @RheumNow( View Tweet )

Jan 31, 2022

Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

https://bit.ly/3yomMYo

Dr. John Cush @RheumNow( View Tweet )

Dec 13, 2021

New Insights into Uveitis in Spondyloarthritis
Save

Antoni Chan, MD, PhD

Dec 01, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in

Read Article

Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.https://t.co/6zARkjsoCg

Links:

https://bit.ly/3cGTHxi

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021

Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt

sheila @RHEUMarampa( View Tweet )

Nov 09, 2021

New Insights into Uveitis in Spondyloarthritis
Save

Antoni Chan, MD, PhD

Nov 09, 2021

Read Article

Adults with #JIA #uveitis are still affected into adulthood. @Mara_Becker discusses visual outcomes #ACR21 https://t.co/ZBjw1CfSmv

Sheila Angeles-Han @STHanMD( View Tweet )

Nov 08, 2021

#Uveitis is the most ⬆ freq xtra-articular manifestation in axSpA. What factors are assoc'd w/AAU attacks? 👁‍🗨Active disease 👁‍🗨History of AAU Bottomline: Treat axSpA, treat uveitis = better outcomes. @RheumNow #ACR21 abs1314 https://t.co/O0kHulwJoP

sheila @RHEUMarampa( View Tweet )

Nov 08, 2021

axSpA and Uveitis Uveitis 🔼 in HLA-B27; Disease duration; Latin American pts 🔽 in Psoriasis ⭐️Uveitis was not significantly different in axSpA vs pSpA Recurrent Uveitis 🔼disease duration and body mass index (BMI) Abst #1307 #ACR21 @Rheumnow https://t.co/QDg8tOPgir

swethaann23 @swethaann23( View Tweet )

Nov 08, 2021

Knowledge Bowl at #ACR21 ⭐️Which HLA allele confers an increased risk for anterior uveitis and inflammatory sacroillitis? ➡️HLA-B27 @RheumNow

Meral K. El Ramahi, MD @MeralElRamahiMD( View Tweet )

Nov 08, 2021

Low incidence of GI-related serious AE in pooled 1 year data from VOY1&2 and DISC1&2 trials of Guselkumab for PsA/PsO treatment ⭐️no new onset IBD or exacerbation of IBD ⭐️no uveitis, infections, TB Abs#1342 #ACR21 @RheumNow https://t.co/x3OmLgInV0

Links:

Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Am…

Robert B Chao, MD @doctorRBC( View Tweet )

Nov 08, 2021

ACR21 Best Abstracts - Day 2
Save

Jack Cush, MD

Nov 07, 2021

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

Read Article

Image of Takayasu's retinopathy (compared to normal) presented by John Stone #ACR21 . I'm no eye doctor, but this cannot be good. @RheumNow https://t.co/rjoQZ8TGDz

Richard Conway @RichardPAConway( View Tweet )

Nov 07, 2021

Recent Blogs

My Take on New Ocular Screening Guidelines for Plaquenil
Save

Sergio Schwartzman, MD

Oct 14, 2016

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).Read Post